Refine
Has Fulltext
- yes (75)
Is part of the Bibliography
- yes (75)
Year of publication
Document Type
- Journal article (75) (remove)
Language
- English (75) (remove)
Keywords
- breast cancer (18)
- ovarian cancer (7)
- 3D printing (4)
- expression (4)
- gynecology (4)
- survival (4)
- education (3)
- inflammation (3)
- ketogenic diet (3)
- teaching (3)
- Akt (2)
- BRENDA (2)
- CD39 (2)
- CD73 (2)
- Ketogenic diet (2)
- Metastatic breast cancer (2)
- NSG (2)
- T cells (2)
- VEGF (2)
- adenosine (2)
- apoptosis (2)
- autophagy (2)
- blood-brain barrier (2)
- cancer (2)
- cancer detection and diagnosis (2)
- cytokines (2)
- disease (2)
- gene (2)
- glioma (2)
- humanized mice (2)
- immune escape (2)
- lymph nodes (2)
- pelvic examination (2)
- pelvic palpation (2)
- pregnancy (2)
- prognosis (2)
- stress (2)
- trastuzumab (2)
- tumor stem cells (2)
- visualization (2)
- 2-APB (1)
- 3D tissue model (1)
- 3D-conformal radiotherapy (1)
- ADCC (1)
- Astrocytic tumor (1)
- Axonal degeneration (1)
- B7-H1 (1)
- Blood–brain barrier (1)
- Blut (1)
- CD74 (1)
- COVID-19 (1)
- CX3CL1 (1)
- CXCL13 (1)
- Ca2+ release activated Ca2+ channel (1)
- Chirurgie (1)
- Coronavirus Disease 2019 (1)
- Covid-19 (1)
- DNA repair protraction (1)
- Diabetic polyneuropathy (1)
- Epidural Analgesia (1)
- Expression (1)
- FDM (1)
- FWGE (1)
- Fettgehalt (1)
- Genetic causes of cancer (1)
- Glioblastoma cell line (1)
- Glioblastoma multiforme (1)
- HER2 (1)
- HER2 conversion (1)
- HER2 targeted therapy (1)
- HER2-low (1)
- HERV-K (1)
- HLA class II (1)
- HLA peptidome (1)
- Health care service research (1)
- Healthcare Cost (1)
- Healthcare Economics (1)
- High fat diet (1)
- Human endogenous retrovirus (1)
- In vitro models (1)
- Ketogene Kost (1)
- Krebs <Medizin> (1)
- Krebskranker (1)
- L. reuteri (1)
- LPS (1)
- Labour Analgesia (1)
- Labour Pain (1)
- Large loop excision of the transformation zone (LLETZ) (1)
- Lebensqualität (1)
- Loop electrosurgical excision procedure (LEEP) (1)
- MMP (1)
- MRSA (1)
- MRSA - methicillin-resistant Staphylococcus aureus (1)
- Matrix metalloproteinases (1)
- Medicine (1)
- Medizin (1)
- Molecular biology (1)
- Motor nerve biopsy (1)
- NRG1 (1)
- NSG-SGM3 (1)
- NVP-BEZ235 (1)
- Nectin‐2 (1)
- Neuropathy (1)
- Neurotrophic factors (1)
- Non-coding RNAs (1)
- Novel PI3K (1)
- PC-1 blockade (1)
- PCR analysis (1)
- PD-1 (1)
- PD-L1 (1)
- Parkinson’s disease (1)
- Patient Controlled Analgesia (1)
- Patient Satisfaction (1)
- Patient-centered registry (1)
- Patient’s needs (1)
- Pelvisio® (1)
- RANK-L inhibitors (1)
- RCTs (1)
- RT-qPCT (1)
- Remifentanil (1)
- SH-6 (1)
- SLA (1)
- SOCE (1)
- SREs (1)
- Severe Acute Respiratory Syndrome Coronavirus 2 (1)
- Staphylococcus aureus (1)
- Staphylococcus aureus immune response (1)
- T-DM1 (1)
- TGF-beta (1)
- TKTL1 (1)
- Toll-like receptor signaling (1)
- UME6 (1)
- VE-cadherin (1)
- accessibility (1)
- acute respiratory distress syndrome (1)
- advanced breast cancer (1)
- age factors (1)
- aged (1)
- aged 80 and over (1)
- animal models (1)
- anti-hormonal therapy (1)
- anti-tumor effects (1)
- argeted therapy (1)
- ascites (1)
- astrocytic tumor (1)
- astrocytoma (1)
- axillary dissection (1)
- bacteria (1)
- bacterial infection model (1)
- benzoquinone (1)
- bioimpedance analysis (1)
- bioinformatics (1)
- biomarker (1)
- bioreactor culture (1)
- bisphosphonates (1)
- blood lipids; fat loss; running performance (1)
- blood-brain barrier (BBB) model (1)
- bone metastases (1)
- brain metastases (1)
- brain metastasis (1)
- brain-metastasis (1)
- breast cancer imaging (1)
- breast cancer metastases (1)
- breast cancer subtypes (1)
- cachexia (1)
- calprotectin (1)
- cancer cell lines (1)
- cancer cells (1)
- cancer chemotherapy (1)
- cancer dissemination (1)
- cancer microenvironment (1)
- cancer patients (1)
- cancer risk factors (1)
- cancer stem cell immunology (1)
- cancer stem cells (1)
- cancer treatment (1)
- cardiac morbidity (1)
- cardiac mortality (1)
- cell lung cancer (1)
- cervical dysplasia (1)
- chemotherapy (1)
- chronic periodontitis (1)
- claudin 5 (1)
- co-culture (1)
- cohort study (1)
- combinatorial drug predictions (1)
- common variable immunodeficiency (CVID) (1)
- conventional imaging (1)
- cord blood (1)
- cross-sectional imaging (1)
- cytostatic (1)
- cytotoxicity (1)
- delay of therapy (1)
- digital medicine (1)
- diseases of the nervous system (1)
- dysplasia (1)
- early breast cancer (1)
- endocrine therapy (1)
- epidemiology (1)
- evidence‐based medicine (1)
- exercise (1)
- exosomes (1)
- expression pattern (1)
- feasibility (1)
- fecal short-chain fatty acids (1)
- female (1)
- fiber intake (1)
- follow up (1)
- fused deposition modeling (FDM) (1)
- gene expression (1)
- genetic testing (1)
- genital warts (1)
- geographic information science (1)
- glioblastoma (1)
- glioblastoma cell-lines (1)
- glioblastoma multiforme (1)
- glioblastoma stem cell (1)
- glioma-associated microglia and macrophages; (1)
- gliomas (1)
- glucose (1)
- growth (1)
- growth differentiation factor 15 (1)
- guideline adherent treatment (1)
- gynecologic surgical procedures/methods (1)
- health care providers (1)
- health care service research (1)
- histology (1)
- histopathology (1)
- hormona therapy (1)
- hormones (1)
- human genetics (1)
- human induced pluripotent stem cells (hiPSCs)human induced pluripotent stem cells (hiPSCs) (1)
- human papillomavirus (1)
- humanized hemato-lymphoid mice (1)
- hyaluronan-related enzymes (1)
- hypoxia (1)
- immune polarization (1)
- immune response (1)
- immune therapy (1)
- immunohistochemistry (1)
- immunoresistance (1)
- immunosurveillance (1)
- immunotherapies (1)
- immunotherapy (1)
- implementation (1)
- inborn errors of immunity (IEIs) (1)
- individual mind state (1)
- inflammatory cascades (1)
- insulin (1)
- insulin-like growth factor 1 (IGF1) (1)
- intestinal inflammation (1)
- intestinal permeability (1)
- invasiveness (1)
- ionizing radiation (1)
- ketogenic dients (1)
- ketone bodies (1)
- laparoscopy/methods (1)
- large loop excision of the transformation zone (LLETZ) (1)
- latency (1)
- lifestyle habits (1)
- low carb diet (1)
- low carbohydrate diet (1)
- lung-cancer (1)
- m-Health (1)
- mTOR Inhibitor (1)
- mammography (1)
- matrix metalloproteinase (1)
- medicine (1)
- melanoma (1)
- metabolic profile (1)
- metabolism (1)
- metastasis (1)
- miRNA (1)
- miRNAs (1)
- mice (1)
- microRNA (1)
- microarray (1)
- microbiota (1)
- microglia (1)
- microna profiles (1)
- middle Aged (1)
- modular tumor tissue models (1)
- monocyte (1)
- monocyte subsets (1)
- monocytes (1)
- morphogenesis (1)
- motivational level (1)
- mouse brain (1)
- multiple sclerosis (1)
- multipotent fetal neural stem cells (fNSCs) (1)
- neoadjuvant therapies (1)
- neonatal immunology (1)
- neural stem cell (1)
- neurodegeneration (1)
- neurogenesis (1)
- neuroimmunology (1)
- neuroinflammation (1)
- neurological disorders (1)
- neurovascular unit in vitro (1)
- number of (1)
- p53 (1)
- pathways (1)
- patient safety (1)
- patient serum (1)
- pelvic organ prolapse/surgery (1)
- peripheral blood (1)
- peritoneal metastasis (1)
- pertuzumab (1)
- pilot study (1)
- plaque (1)
- polyvinylidene fluoride (PVDF) (1)
- positive nodal status (1)
- post-neoadjuvant therapies (1)
- postoperative complications/epidemiology (1)
- postpartum (1)
- prediction (1)
- pregnancy gingivitis (1)
- premalignant lesion (1)
- preterm infants (1)
- primary immunodeficiency (1)
- probiotic lozenges (1)
- prognostic marker (1)
- psychological distress (1)
- quality of care (1)
- quality of life (1)
- radiosensibility (1)
- reactive oxygen species (1)
- reconstructive surgical procedures/methods (1)
- regulator (1)
- rehabilitation (1)
- retrospective Studies (1)
- review (1)
- rheumatoid arthritis (1)
- risk (1)
- robotic complications (1)
- robotic hysterectomy (1)
- robotic sacrocolpopexy (1)
- safety (1)
- score (1)
- seahorse (1)
- sentinel (1)
- serum (1)
- signature (1)
- simulation (1)
- skeleton (1)
- staib agar (1)
- staphylocccal infection/epidemiology (1)
- staphylococcal abscess (1)
- stromal hyaluronan (1)
- subgingival (1)
- subventricular zone (1)
- supportive care (1)
- surgical Mesh (1)
- survivors (1)
- symptom burden (1)
- therapy (1)
- transforming growth factor-beta-1 (1)
- trastuzumab deruxtecan (1)
- tumor associated macrophages (1)
- tumor dormancy (1)
- tumor immune escape (1)
- tumor immunology (1)
- tumor immunosurveillance (1)
- tumor infiltrating lymphocytes (1)
- tumor microenvironment (1)
- tumor size (1)
- tumor-associated hyaluronan staining pattern (1)
- tumor-infiltrating lymphocytes (1)
- tumor-propagating cells (1)
- tumors (1)
- tumour immunology (1)
- ultrasound (1)
- unmet needs (1)
- urinary incontinence/surgery (1)
- uterine prolapse/surgery (1)
- vagina/surgery (1)
- vascular permeability (1)
- viral load (1)
- virtual (1)
- virulence (1)
- zonulin (1)
- β-Hydroxybutyrate (1)
Institute
- Frauenklinik und Poliklinik (75) (remove)
EU-Project number / Contract (GA) number
- 259867 (1)
Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients
(2021)
In recent years, significant progress has been made in new therapeutic approaches to breast cancer, particularly in patients with HER2-positive and HER2-negative/hormone receptor-positive (HR+) breast cancer. In the case of HER2-positive tumours, these approaches have included, in particular, treatment with pertuzumab, T-DM1, neratinib and, soon, also tucatinib and trastuzumab deruxtecan (neither of which has yet been authorised in Europe). In patients with HER2−/HR+ breast cancer, CDK4/6 inhibitors and the PIK3CA inhibitor alpelisib are of particular importance. Further novel therapies, such as Akt kinase inhibitors and oral SERDs (selective estrogen receptor down regulators), are already being investigated in ongoing clinical trials. These therapeutic agents are not only being introduced into curative, (neo-)adjuvant therapeutic settings for HER2-positive tumours; a first favourable study on abemaciclib as an adjuvant therapy has now also been published. In patients with triple-negative breast cancer, after many years of negative study results with the Trop-2 antibody drug conjugate (ADC) sacituzumab govitecan, a randomised study has been published that may represent a significant therapeutic advance. This review describes the latest developments in breast cancer subsequent to the ESMO Congress 2020.
While the central nervous system is considered an immunoprivileged site and brain tumors display immunosuppressive features, both innate and adaptive immune responses affect glioblastoma (GBM) growth and treatment resistance. However, the impact of the major immune cell population in gliomas, represented by glioma-associated microglia/macrophages (GAMs), on patients’ clinical course is still unclear. Thus, we aimed at assessing the immunohistochemical expression of selected microglia and macrophage markers in 344 gliomas (including gliomas from WHO grade I–IV). Furthermore, we analyzed a cohort of 241 IDH1R132H-non-mutant GBM patients for association of GAM subtypes and patient overall survival. Phenotypical properties of GAMs, isolated from high-grade astrocytomas by CD11b-based magnetic cell sorting, were analyzed by immunocytochemistry, mRNA microarray, qRT-PCR and bioinformatic analyses. A higher amount of CD68-, CD163- and CD206-positive GAMs in the vital tumor core was associated with beneficial patient survival. The mRNA expression profile of GAMs displayed an upregulation of factors that are considered as pro-inflammatory M1 (eg, CCL2, CCL3L3, CCL4, PTGS2) and anti-inflammatory M2 polarization markers (eg, MRC1, LGMN, CD163, IL10, MSR1), the latter rather being associated with phagocytic functions in the GBM microenvironment. In summary, we present evidence that human GBMs contain mixed M1/M2-like polarized GAMs and that the levels of different GAM subpopulations in the tumor core are positively associated with overall survival of patients with IDH1R132H-non-mutant GBMs.
Bone-modifying agents like bisphosphonates and receptor activator of nuclear factor kappaβ ligand (RANK-L) inhibitors are used as supportive treatments in breast cancer patients with bone metastases to prevent skeletal-related events (SREs). Due to missing head-to-head comparisons, a network meta-analysis was performed to provide a hierarchy of these therapeutic options. Through a systematic literature search, 21 randomized controlled trials (RCTs) that fulfilled the inclusion criteria were identified. To prevent SREs, the ranking through P-scores showed denosumab (RR: 0.62; 95%CI: 0.50-0.76), zoledronic acid (RR: 0.72; 95%CI: 0.61-0.84) and pamidronate (RR: 0.76; 95%CI: 0.67-0.85) to be significantly superior to placebo. Due to insufficient or heterogeneous data, overall survival, quality of life, pain response and adverse events were not able to be analyzed within the network. Although data were sparse on adverse events, the risk of significant adverse events appeared low. The results of this review can therefore be used to formulate clinical studies more precisely in order to standardise and focus on patient-relevant outcomes.
Purpose
Radiotherapy (RT) was identified as a risk factor for long-term cardiac effects in breast cancer patients treated until the 1990s. However, modern techniques reduce radiation exposure of the heart, but some exposure remains unavoidable. In a retrospective cohort study, we investigated cardiac mortality and morbidity of breast cancer survivors treated with recent RT in Germany.
Methods
A total of 11,982 breast cancer patients treated between 1998 and 2008 were included. A mortality follow-up was conducted until 06/2018. In order to assess cardiac morbidity occurring after breast cancer treatment, a questionnaire was sent out in 2014 and 2019. The effect of breast cancer laterality on cardiac mortality and morbidity was investigated as a proxy for radiation exposure. We used Cox Proportional Hazards regression analysis, taking potential confounders into account.
Results
After a median follow-up time of 11.1 years, there was no significant association of tumor laterality with cardiac mortality in irradiated patients (hazard ratio (HR) for left-sided versus right-sided tumor 1.09; 95% confidence interval (CI) 0.85–1.41). Furthermore, tumor laterality was not identified as a significant risk factor for cardiac morbidity (HR = 1.05; 95%CI 0.88–1.25).
Conclusions
Even though RT for left-sided breast cancer on average incurs higher radiation dose to the heart than RT for right-sided tumors, we found no evidence that laterality is a strong risk factor for cardiac disease after contemporary RT. However, larger sample sizes, longer follow-up, detailed information on individual risk factors and heart dose are needed to assess clinically manifest late effects of current cancer therapy.
Next-generation humanized NSG-SGM3 mice are highly susceptible to Staphylococcus aureus infection
(2023)
Humanized hemato-lymphoid system mice, or humanized mice, emerged in recent years as a promising model to study the course of infection of human-adapted or human-specific pathogens. Though Staphylococcus aureus infects and colonizes a variety of species, it has nonetheless become one of the most successful human pathogens of our time with a wide armory of human-adapted virulence factors. Humanized mice showed increased vulnerability to S. aureus compared to wild type mice in a variety of clinically relevant disease models. Most of these studies employed humanized NSG (NOD-scid IL2Rgnull) mice which are widely used in the scientific community, but show poor human myeloid cell reconstitution. Since this immune cell compartment plays a decisive role in the defense of the human immune system against S. aureus, we asked whether next-generation humanized mice, like NSG-SGM3 (NOD-scid IL2Rgnull-3/GM/SF) with improved myeloid reconstitution, would prove to be more resistant to infection. To our surprise, we found the contrary when we infected humanized NSG-SGM3 (huSGM3) mice with S. aureus: although they had stronger human immune cell engraftment than humanized NSG mice, particularly in the myeloid compartment, they displayed even more pronounced vulnerability to S. aureus infection. HuSGM3 mice had overall higher numbers of human T cells, B cells, neutrophils and monocytes in the blood and the spleen. This was accompanied by elevated levels of pro-inflammatory human cytokines in the blood of huSGM3 mice. We further identified that the impaired survival of huSGM3 mice was not linked to higher bacterial burden nor to differences in the murine immune cell repertoire. Conversely, we could demonstrate a correlation of the rate of humanization and the severity of infection. Collectively, this study suggests a detrimental effect of the human immune system in humanized mice upon encounter with S. aureus which might help to guide future therapy approaches and analysis of virulence mechanisms.
Introduction: National and international guidelines recommend early integration of evidence-based multimodal interventions and programs, especially with a focus on relaxation techniques and other Mind–Body-based methods to maintain the quality of life of oncology patients, improve treatment tolerability, and promote healthy lifestyle behaviors. Consequently, we aim to understand what drives patients and how they navigate integrative medicine to best advise them. This study aimed to detect possible topics of particular interest to patients and identify the patient groups that could benefit most from further programs. Furthermore, we aimed to investigate if patients are open-minded toward integrative oncology concepts and learn about their motivational level to maintain or change behavior.
Methods: Between August 2019 and October 2020 we surveyed patients undergoing oncological therapy in a university oncological outpatient center using a custom-developed questionnaire based on established Mind–Body Medicine concepts.
Results: We included 294 patients with various cancers. More than half reported problems sleeping through (61%) and 42% felt stressed frequently, invariably rating this as detrimental to their health. Moreover, a slight majority (52%) felt physically limited due to their disease and only 30% performed defined exercise programs. Women were significantly more likely to feel stressed and reported with alarming frequency that they often feel “everything was up to them.” The 40–65-year-olds reported significantly less restful sleep, more stress and were more dissatisfied with their situation. However, this group already used natural remedies most frequently and was most often motivated to use relaxation techniques in the next 6 months. The lower the perceived individual energy level (EL), the less frequently patients did sport, the more frequently they felt their disease impaired their activity, mostly feeling stressed and tense. We also found significant associations between negative emotions/thoughts and the variables “sleep,” “use of relaxation techniques,” “personal stress perception,” and “successful lifestyle modification.”
Conclusion: Mind–Body programs that focus on patient’s individual resources, with tools to explore impairing patterns of self-perception and cognitive biases, can be a valuable resource for oncology patients and should therefore be part of an integrative medical treatment concept.
Immune checkpoint blockade therapy is beneficial and even curative for some cancer patients. However, the majority don’t respond to immune therapy. Across different tumor types, pre-existing T cell infiltrates predict response to checkpoint-based immunotherapy. Based on in vitro pharmacological studies, mouse models and analyses of human melanoma patients, we show that the cytokine GDF-15 impairs LFA-1/β2-integrin-mediated adhesion of T cells to activated endothelial cells, which is a pre-requisite of T cell extravasation. In melanoma patients, GDF-15 serum levels strongly correlate with failure of PD-1-based immune checkpoint blockade therapy. Neutralization of GDF-15 improves both T cell trafficking and therapy efficiency in murine tumor models. Thus GDF-15, beside its known role in cancer-related anorexia and cachexia, emerges as a regulator of T cell extravasation into the tumor microenvironment, which provides an even stronger rationale for therapeutic anti-GDF-15 antibody development.
Increased intestinal permeability and inflammation, both fueled by dysbiosis, appear to contribute to rheumatoid arthritis (RA) pathogenesis. This single-center pilot study aimed to investigate zonulin, a marker of intestinal permeability, and calprotectin, a marker of intestinal inflammation, measured in serum and fecal samples of RA patients using commercially available kits. We also analyzed plasma lipopolysaccharide (LPS) levels, a marker of intestinal permeability and inflammation. Furthermore, univariate, and multivariate regression analyses were carried out to determine whether or not there were associations of zonulin and calprotectin with LPS, BMI, gender, age, RA-specific parameters, fiber intake, and short-chain fatty acids in the gut. Serum zonulin levels were more likely to be abnormal with a longer disease duration and fecal zonulin levels were inversely associated with age. A strong association between fecal and serum calprotectin and between fecal calprotectin and LPS were found in males, but not in females, independent of other biomarkers, suggesting that fecal calprotectin may be a more specific biomarker than serum calprotectin is of intestinal inflammation in RA. Since this was a proof-of-principle study without a healthy control group, further research is needed to validate fecal and serum zonulin as valid biomarkers of RA in comparison with other promising biomarkers.
Abstract
Despite multidisciplinary local and systemic therapeutic approaches, the prognosis for most patients with brain metastases is still dismal. The role of adaptive and innate anti-tumor response including the Human Leukocyte Antigen (HLA) machinery of antigen presentation is still unclear. We present data on the HLA class II-chaperone molecule CD74 in brain metastases and its impact on the HLA peptidome complexity.
We analyzed CD74 and HLA class II expression on tumor cells in a subset of 236 human brain metastases, primary tumors and peripheral metastases of different entities in association with clinical data including overall survival. Additionally, we assessed whole DNA methylome profiles including CD74 promoter methylation and differential methylation in 21 brain metastases. We analyzed the effects of a siRNA mediated CD74 knockdown on HLA-expression and HLA peptidome composition in a brain metastatic melanoma cell line.
We observed that CD74 expression on tumor cells is a strong positive prognostic marker in brain metastasis patients and positively associated with tumor-infiltrating T-lymphocytes (TILs). Whole DNA methylome analysis suggested that CD74 tumor cell expression might be regulated epigenetically via CD74 promoter methylation. CD74\(^{high}\) and TIL\(^{high}\) tumors displayed a differential DNA methylation pattern with highest enrichment scores for antigen processing and presentation. Furthermore, CD74 knockdown in vitro lead to a reduction of HLA class II peptidome complexity, while HLA class I peptidome remained unaffected.
In summary, our results demonstrate that a functional HLA class II processing machinery in brain metastatic tumor cells, reflected by a high expression of CD74 and a complex tumor cell HLA peptidome, seems to be crucial for better patient prognosis.